Is BillionToOne a startup?
BillionToOne has evolved past its early-stage startup origins into a publicly traded commercial-stage molecular diagnostics enterprise. Founded originally as a venture-backed health-tech startup focused on developing single-molecule DNA counting innovations, the company has since scaled its commercial operations significantly, achieved substantial annual revenues, and completed its public market debut. While it maintains the rapid innovation pace, research-driven culture, and growth orientation typical of modern biotechnology companies, its large institutional backing, expansive commercial footprint, and public corporation status place it well beyond standard early-stage startup definitions.
Related FAQs
American Express Membership Rewards points possess a flexible valuation that varies significantly depending on how you choose to redeem them, meaning their cash value is not a fixed amount.
Bitdeer Technologies Group commands a corporate market capitalization of approximately $2.81 billion USD.
Yes, BillionToOne operates as a publicly traded enterprise. The molecular diagnostics and precision medicine company successfully completed its initial public offering on the NASDAQ Global Select Market, trading under the ticker symbol BLLN.
BillionToOne is widely regarded as an innovative, fast-growing molecular diagnostics and precision health company specializing in advanced prenatal screening and oncology liquid biopsy testing.
Yes, clinical tests offered by BillionToOne—such as its UNITY prenatal screen and Northstar oncology liquid biopsy panels—are widely covered by Medicare, Medicaid, and major private commercial health insurance providers.
Yes, BillionToOne, Inc. is a publicly traded enterprise.